Adoptive transfer of 67NR-primed CD19+ B cells into 4T1-bearing immunocompetent or immunodeficient hosts preserved bone architecture, reduced RANKL production, inhibited metastases, and limited tumor growth. The gene discussed is CD19; the disease is neoplasm.